Prior notification of a concentration (Case M.10826 – GOLDMAN SACHS / NORGINE) Candidate case for simplified procedure (Text with EEA relevance) 2022/C 333/11
Date: 2022-09-01
Institutions: Directorate-General for Competition, European Commission
Subjects: Netherlands, banking, economic concentration, investment, investment company, merger control, pharmaceutical industry, provision of services, securities








C_2022333EN.01001201.xml










1.9.2022   


EN


Official Journal of the European Union


C 333/12






Prior notification of a concentration
(Case M.10826 – GOLDMAN SACHS / NORGINE)
Candidate case for simplified procedure
(Text with EEA relevance)
(2022/C 333/11)

1.   
On 24 August 2022, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1).
This notification concerns the following undertakings:






—


The Goldman Sachs Group, Inc. (‘Goldman Sachs’, United States of America);










—


Norgine Europe B.V. together with its direct and indirect subsidiaries (‘the Norgine Group’ or the ‘Target’, Netherlands).




Goldman Sachs will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of Norgine (2).
The concentration is accomplished by way of purchase of shares.


2.   
The business activities of the undertakings concerned are the following:






—


Goldman Sachs is a global investment banking, securities and investment management firm that provides a range of banking, securities and investment services worldwide to a substantial and diversified client base that includes corporations, financial institutions, governments and high-net-worth individuals,










—


The Norgine Group, which is headquartered in the Netherlands, is a European specialist pharmaceutical company that develops, manufactures, and markets pharmaceutical goods mainly for the following therapeutic areas: gastroenterology, hepatology, emergency care, haematology, obstetrics, cardiology, oncology, urology, and neurology.






3.   
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (3) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.


4.   
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10826 – GOLDMAN SACHS / NORGINE
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:





European Commission




Directorate-General for Competition




Merger Registry




1049 Bruxelles/Brussel




BELGIQUE/BELGIË







(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

(2)  Prior to completion of the Transaction, Norgine Ventures B.V. and its direct and indirect subsidiaries (‘Norgine Ventures’) will be carved out from the Norgine Group, which is the Target of the Transaction.

(3)  OJ C 366, 14.12.2013, p. 5.